Journal of Clinical Oncology, Vol 19, Issue 10
(May), 2001: 2587-2595
© 2001 American Society for Clinical Oncology
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
By Andrew D. Seidman,
Monica N. Fornier,
Francisco J. Esteva,
Lee Tan,
Stamatina Kaptain,
Ariadne Bach,
Katherine S. Panageas,
Crispinita Arroyo,
Vicente Valero,
Violante Currie,
Teresa Gilewski,
Maria Theodoulou,
Mary Ellen Moynahan,
Mark Moasser,
Nancy Sklarin,
Maura Dickler,
Gabriella D’Andrea,
Massimo Cristofanilli,
Edgardo Rivera,
Gabriel N. Hortobagyi,
Larry Norton,
Clifford A. Hudis
From the Breast Cancer Medicine Service, Department of Pathology, Department of Radiology, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; and Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Address reprint requests to Andrew D. Seidman, MD, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: seidmana{at}mskcc.org
PURPOSE: This phase II study evaluated weekly trastuzumab and paclitaxel therapy in women with HER2-normal and HER2-overexpressing metastatic breast cancer. Efficacy was correlated with immunohistochemical and fluorescent in situ hybridization (FISH) assay results.
PATIENTS AND METHODS: Eligible patients had bidimensionally measurable metastatic breast cancer. Up to three prior chemotherapy regimens, including prior anthracycline and taxane therapy, were allowed. Trastuzumab 4 mg/kg and paclitaxel 90 mg/m2 were administered on week 1, with trastuzumab 2 mg/kg and paclitaxel 90 mg/m2 administered on subsequent weeks. HER2 status was evaluated using four different immunohistochemical assays and FISH.
RESULTS: Patients received a median of 25 weekly infusions (range, one to 85 infusions). Median delivered paclitaxel dose-intensity was 82 mg/m2/wk (range, 52 to 90 mg/m2/wk). The intent-to-treat response rate for all 95 patients enrolled was 56.8% (95% confidence interval, 47% to 67%). A response rate of 61.4% (4.5% complete response, 56.8% partial response) was observed in 88 fully assessable patients. In patients with HER2-overexpressing tumors, overall response rates ranged from 67% to 81% compared with 41% to 46% in patients with HER2-normal expression (ranges reflect the different assay methods used to assess HER2 status). Differences in response rates between patients with HER2-overexpressing tumors and those with normal HER2 expression were statistically significant for all assay methods, with CB11 and TAB250 antibodies and FISH having the strongest significance. Therapy was generally well tolerated, although three patients had serious cardiac complications.
CONCLUSION: Weekly trastuzumab and paclitaxel therapy is active in women with metastatic breast cancer. Therapy was relatively well tolerated; however, attention to cardiac function is necessary.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
N. T. Okita, Y. Yamada, D. Takahari, Y. Hirashima, J. Matsubara, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, H. Taniguchi, et al.
Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer
Jpn. J. Clin. Oncol.,
June 17, 2009;
(2009)
hyp066v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Slamon and M. F. Press
Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers
J Natl Cancer Inst,
May 6, 2009;
101(9):
615 - 618.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist,
April 1, 2009;
14(4):
320 - 368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
J. Clin. Oncol.,
March 10, 2009;
27(8):
1323 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Oncologist,
January 1, 2009;
14(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. Santiago, R. Guzman, A. Gasparyan, Y. Ma, et al.
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Clin. Cancer Res.,
December 1, 2008;
14(23):
7861 - 7870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Vanden Bempt, P. Van Loo, M. Drijkoningen, P. Neven, A. Smeets, M.-R. Christiaens, R. Paridaens, and C. De Wolf-Peeters
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
J. Clin. Oncol.,
October 20, 2008;
26(30):
4869 - 4874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bullock and K. Blackwell
Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer
Oncologist,
May 1, 2008;
13(5):
515 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, P. K. Marcom, G. Gipson, H. Burstein, D. Lake, C. L. Shapiro, et al.
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
J. Clin. Oncol.,
April 1, 2008;
26(10):
1642 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Esteva
Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2-Negative Breast Cancer?
Oncologist,
April 1, 2008;
13(4):
370 - 372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez, V. J. Suman, N. E. Davidson, G. W. Sledge, P. A. Kaufman, C. A. Hudis, S. Martino, J. R. Gralow, S. R. Dakhil, J. N. Ingle, et al.
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
J. Clin. Oncol.,
March 10, 2008;
26(8):
1231 - 1238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Raponi, J. E. Lancet, H. Fan, L. Dossey, G. Lee, I. Gojo, E. J. Feldman, J. Gotlib, L. E. Morris, P. L. Greenberg, et al.
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
Blood,
March 1, 2008;
111(5):
2589 - 2596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Katsumi, Y. Kuwahara, S. Tamura, K. Kikuchi, O. Otabe, K. Tsuchiya, T. Iehara, H. Kuroda, H. Hosoi, and T. Sugimoto
Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Clin. Cancer Res.,
February 15, 2008;
14(4):
1192 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
J. Clin. Pathol.,
January 1, 2008;
61(1):
89 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med.,
July 5, 2007;
357(1):
39 - 51.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Ewend, S. Brem, M. Gilbert, R. Goodkin, P. L. Penar, M. Varia, S. Cush, and L. A. Carey
Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control
Clin. Cancer Res.,
June 15, 2007;
13(12):
3637 - 3641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Dendukuri, K. Khetani, M. McIsaac, and J. Brophy
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis
Can. Med. Assoc. J.,
May 8, 2007;
176(10):
1429 - 1434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, and R. Schiff
Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
J Natl Cancer Inst,
May 2, 2007;
99(9):
694 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist,
March 1, 2007;
12(3):
253 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gonzalez-Angulo, G. N. Hortobagyi, and F. J. Esteva
Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer
Oncologist,
September 1, 2006;
11(8):
857 - 867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Egervari, Z Szollosi, and Z Nemes
Reply to "IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma"
J. Clin. Pathol.,
June 1, 2006;
59(6):
665 - 665.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al.
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients.
Clin. Cancer Res.,
May 15, 2006;
12(10):
3124 - 3129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al.
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
Ann. Onc.,
April 1, 2006;
17(4):
630 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Eniu, F. M. Palmieri, and E. A. Perez
Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer
Oncologist,
October 1, 2005;
10(9):
665 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, et al.
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
J. Clin. Oncol.,
July 1, 2005;
23(19):
4265 - 4274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kimura, H. Tsuda, D. Morita, E. Shinto, T. Tanimoto, T. Ichikura, H. Mochizuki, and O. Matsubara
Usefulness and Limitation of Multiple Endoscopic Biopsy Sampling for Epidermal Growth Factor Receptor and c-erbB-2 Testing in Patients with Gastric Adenocarcinoma
Jpn. J. Clin. Oncol.,
June 1, 2005;
35(6):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Fornier, A. D. Seidman, M. K. Schwartz, F. Ghani, R. Thiel, L. Norton, and C. Hudis
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
Ann. Onc.,
February 1, 2005;
16(2):
234 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez, V. J. Suman, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, J. N. Ingle, R. J. Rodeheffer, B. J. Gersh, and A. S. Jaffe
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
J. Clin. Oncol.,
September 15, 2004;
22(18):
3700 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Parihar, P. Nadella, A. Lewis, R. Jensen, C. De Hoff, J. E. Dierksheide, A. M. VanBuskirk, C. M. Magro, D. C. Young, C. L. Shapiro, et al.
A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies: Analysis of Sustained Interferon {gamma} Production in a Subset of Patients
Clin. Cancer Res.,
August 1, 2004;
10(15):
5027 - 5037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Esteva
Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer
Oncologist,
June 3, 2004;
9(suppl_3):
4 - 9.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nahta, T. Takahashi, N. T. Ueno, M.-C. Hung, and F. J. Esteva
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Cancer Res.,
June 1, 2004;
64(11):
3981 - 3986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al.
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
J Natl Cancer Inst,
May 19, 2004;
96(10):
759 - 769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Burris III, D. Yardley, S. Jones, G. Houston, C. Broome, D. Thompson, F. A. Greco, M. White, and J. Hainsworth
Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer
J. Clin. Oncol.,
May 1, 2004;
22(9):
1621 - 1629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, J. R. Gralow, R. B. Livingston, and A. M. Gown
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
JAMA,
April 28, 2004;
291(16):
1972 - 1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nahta, M.-C. Hung, and F. J. Esteva
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
Cancer Res.,
April 1, 2004;
64(7):
2343 - 2346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics,
April 1, 2004;
3(4):
379 - 398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.L. Tedesco, A.D. Thor, D.H. Johnson, Y. Shyr, K.A. Blum, L.J. Goldstein, W.J. Gradishar, B.P. Nicholson, D.E. Merkel, D. Murrey, et al.
Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial
J. Clin. Oncol.,
March 15, 2004;
22(6):
1071 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol.,
March 1, 2004;
22(5):
854 - 863.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Kostler, B. Schwab, C. F. Singer, R. Neumann, E. Rucklinger, T. Brodowicz, S. Tomek, M. Niedermayr, M. Hejna, G. G. Steger, et al.
Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
Clin. Cancer Res.,
March 1, 2004;
10(5):
1618 - 1624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez and R. Rodeheffer
Clinical Cardiac Tolerability of Trastuzumab
J. Clin. Oncol.,
January 15, 2004;
22(2):
322 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Gatzemeier, G. Groth, C. Butts, N. Van Zandwijk, F. Shepherd, A. Ardizzoni, C. Barton, P. Ghahramani, and V. Hirsh
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Ann. Onc.,
January 1, 2004;
15(1):
19 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, et al.
Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer
Clin. Cancer Res.,
December 1, 2003;
9(16):
5944 - 5951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel
J. Clin. Oncol.,
November 1, 2003;
21(21):
3965 - 3971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nahta and F. J. Esteva
HER-2-Targeted Therapy: Lessons Learned and Future Directions
Clin. Cancer Res.,
November 1, 2003;
9(14):
5078 - 5084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Liang, Y. Lu, W. Jin, K. K. Ang, L. Milas, and Z. Fan
Sensitization of breast cancer cells to radiation by trastuzumab
Mol. Cancer Ther.,
November 1, 2003;
2(11):
1113 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhou, J. Chen, M. Mokotoff, R. Zhong, L. D. Shultz, and E. D. Ball
Bombesin/Gastrin-Releasing Peptide Receptor: A Potential Target for Antibody-Mediated Therapy of Small Cell Lung Cancer
Clin. Cancer Res.,
October 15, 2003;
9(13):
4953 - 4960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Suzuki, Y. Tokuda, Y. Saito, M. Ohta, and T. Tajima
Combination of Trastuzumab and Vinorelbine in Metastatic Breast Cancer
Jpn. J. Clin. Oncol.,
October 1, 2003;
33(10):
514 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Burstein, L. N. Harris, P. K. Marcom, R. Lambert-Falls, K. Havlin, B. Overmoyer, R. J. Friedlander Jr., J. Gargiulo, R. Strenger, C. L. Vogel, et al.
Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
J. Clin. Oncol.,
August 1, 2003;
21(15):
2889 - 2895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist,
August 1, 2003;
8(4):
307 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Camp, M. Dolled-Filhart, B. L. King, and D. L. Rimm
Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome
Cancer Res.,
April 1, 2003;
63(7):
1445 - 1448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A J Lodge, J J Anderson, W J Gullick, B Haugk, R C F Leonard, and B Angus
Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4
J. Clin. Pathol.,
April 1, 2003;
56(4):
300 - 304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nahta, G. N. Hortobagyi, and F. J. Esteva
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Oncologist,
February 1, 2003;
8(1):
5 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Page, D. Assouline, O. Brun, D. Coeffic, D. Fric, P. Winckel, A. D. Seidman, M. K. Pierri, and C. Hudis
Cardiac Dysfunction in Clinical Trials of Trastuzumab
J. Clin. Oncol.,
October 1, 2002;
20(19):
4119 - 4120.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jahanzeb, J. E. Mortimer, F. Yunus, D. H. Irwin, J. Speyer, A. J. Koletsky, P. Klein, T. Sabir, and L. Kronish
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
Oncologist,
October 1, 2002;
7(5):
410 - 417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Soule, L Baldridge, K Kirkpatrick, L Cheng, J L Gilbert, L R Smith, V C Thurston, G H Vance, L Einhorn, and K Miller
HER-2/neu expression in germ cell tumours
J. Clin. Pathol.,
September 1, 2002;
55(9):
656 - 658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Miknyoczki, W. Wan, H. Chang, P. Dobrzanski, B. A. Ruggeri, C. A. Dionne, and K. Buchkovich
The Neurotrophin-Trk Receptor Axes Are Critical for the Growth and Progression of Human Prostatic Carcinoma and Pancreatic Ductal Adenocarcinoma Xenografts in Nude Mice
Clin. Cancer Res.,
June 1, 2002;
8(6):
1924 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tubbs, J. Pettay, M. Skacel, R. Powell, M. Stoler, P. Roche, and J. Hainfeld
Gold-Facilitated in Situ Hybridization : A Bright-Field Autometallographic Alternative to Fluorescence in Situ Hybridization for Detection of HER-2/neu Gene Amplification
Am. J. Pathol.,
May 1, 2002;
160(5):
1589 - 1595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Fritsche, et al.
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer
J. Clin. Oncol.,
April 1, 2002;
20(7):
1800 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Seidman, C. Hudis, M. K. Pierri, S. Shak, V. Paton, M. Ashby, M. Murphy, S. J. Stewart, and D. Keefe
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
J. Clin. Oncol.,
March 1, 2002;
20(5):
1215 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savinainen, O. R. Saramaki, M. J. Linja, O. Bratt, T. L. J. Tammela, J. J. Isola, and T. Visakorpi
Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer
Am. J. Pathol.,
January 1, 2002;
160(1):
339 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Livingston and F. J. Esteva
Chemotherapy and Herceptin for HER-2+ Metastatic Breast Cancer: The Best Drug?
Oncologist,
August 1, 2001;
6(4):
315 - 316.
[Full Text]
[PDF]
|
|
|
|
